- Trials with a EudraCT protocol (46)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
46 result(s) found for: Interleukin 11.
Displaying page 1 of 3.
EudraCT Number: 2020-001172-15 | Sponsor Protocol Number: APN01-01-COVID19 | Start Date*: 2020-04-08 |
Sponsor Name:APEIRON Biologics AG | ||
Full Title: Recombinant human angiotensin-converting enzyme 2 (rhACE2) as a treat-ment for patients with COVID-19 | ||
Medical condition: Severe COVID-19 POSITIVE hospitalized male or female, between 18 and ≤ 80 years of age | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) DK (Completed) AT (Completed) GB (GB - no longer in EU/EEA) | ||
Trial results: View results |
EudraCT Number: 2010-019952-35 | Sponsor Protocol Number: CS001P3 | Start Date*: 2010-09-14 |
Sponsor Name:CEL-SCI Corporation | ||
Full Title: A Phase III, Open-label, Randomized, Multi-center Study of the Effects of Leukocyte Interleukin, Injection [Multikine] Plus Standard of Care (Surgery + Radiotherapy or Surgery + Concurrent Chemorad... | ||
Medical condition: Subjects with Advanced Primary Sqamous Cell Carcinoma of the oral Cavity/Soft Palate | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: HU (Completed) PL (Completed) GB (GB - no longer in EU/EEA) AT (Prematurely Ended) RO (Ongoing) HR (Ongoing) ES (Prematurely Ended) IT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2013-001188-22 | Sponsor Protocol Number: MIMMA | Start Date*: 2013-09-12 |
Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA | ||
Full Title: Interleukin 2 and zolendronic acid as maintaining treatment in multiple myeloma patients after autologous bone marrow transplant | ||
Medical condition: Multiple Myeloma patients underwent to autologous bone marrow transplant | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2016-003858-33 | Sponsor Protocol Number: AM0010-301 | Start Date*: 2017-05-12 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Followi... | |||||||||||||
Medical condition: Advanced Metastatic Pancreatic Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) ES (Completed) DE (Completed) BE (Completed) GB (Completed) PL (Completed) FR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-020065-24 | Sponsor Protocol Number: WA25204 | Start Date*: 2011-08-15 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd. | |||||||||||||
Full Title: A clinical outcomes study to evaluate the effects of IL-6 receptor blockade with tocilizumab (TCZ) in comparison with etanercept (ETA) on the rate of cardiovascular events in patients with moderate... | |||||||||||||
Medical condition: Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) HU (Completed) LV (Completed) BE (Completed) AT (Completed) LT (Completed) CZ (Completed) DE (Completed) ES (Completed) NL (Completed) GR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001571-32 | Sponsor Protocol Number: APHP200406 | Start Date*: 2020-04-15 |
Sponsor Name:Assistance Publique Hôpitaux de Paris | ||
Full Title: Low dose of IL-2 In Acute respiratory DistrEss syndrome related to COVID-19 LILIADE-COVID | ||
Medical condition: COVID-19 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2019-004141-32 | Sponsor Protocol Number: M19-977 | Start Date*: 2020-09-24 | |||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
Full Title: A Randomized, Active-Controlled, Efficacy Assessor-Blinded Study to Evaluate Pharmacokinetics, Safety and Efficacy of Risankizumab in Patients from 6 to Less than 18 Years of Age with Moderate to S... | |||||||||||||
Medical condition: Plaque Psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA PL (Trial now transitioned) DE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-003444-30 | Sponsor Protocol Number: C0743T12 | Start Date*: 2007-05-15 | |||||||||||
Sponsor Name:Centocor B.V. | |||||||||||||
Full Title: A Phase 3, Multicenter, Randomized Study Comparing CNTO 1275 and Etanercept for the Treatment of Moderate to Severe Plaque Psoriasis | |||||||||||||
Medical condition: Moderate to Severe Plaque Psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) DE (Completed) BE (Completed) NL (Completed) GB (Completed) AT (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005154-57 | Sponsor Protocol Number: CACZ885D2307E1 | Start Date*: 2012-01-03 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: An open-label extension study to assess efficacy, safety and tolerability of canakinumab and the efficacy and safety of childhood vaccinations in patients with Cryopyrin Associated Periodic Syndrom... | |||||||||||||
Medical condition: Cryopyrin Associated Periodic Syndromes (CAPS) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) FR (Completed) ES (Completed) DE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001540-56 | Sponsor Protocol Number: 208657 | Start Date*: 2019-08-18 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||
Full Title: A multi-center, randomized, double-blind, parallel-group, placebo controlled study of mepolizumab 100 mg SC as add-on treatment in participants with COPD experiencing frequent exacerbations and cha... | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) HU (Ongoing) ES (Ongoing) NL (Ongoing) DK (Ongoing) BE (Ongoing) DE (Ongoing) SE (Ongoing) IE (Ongoing) IT (Ongoing) GR (Ongoing) AT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-023562-51 | Sponsor Protocol Number: BT-CL-PGG-CRC1031 | Start Date*: 2011-11-17 | |||||||||||
Sponsor Name:Biothera | |||||||||||||
Full Title: A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG® in Combination with Cetuximab (Erbitux®) in Subjects with Recurrent or Progressive KRAS Wild Type Colorectal Cancer | |||||||||||||
Medical condition: Recurrent or Progressive KRAS Wild Type Colorectal Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-005406-54 | Sponsor Protocol Number: M14TIL | Start Date*: 2014-05-09 | ||||||||||||||||
Sponsor Name:Antoni van Leeuwenhoek ziekenhuis | ||||||||||||||||||
Full Title: Randomized phase III study comparing a non-myeloablative lymphocyte depleting regimen of chemotherapy followed by infusion of tumor infiltrating lymphocytes and interleukin-2 to standard ipilimumab... | ||||||||||||||||||
Medical condition: Patients with unresectable and metastatic (stage IIIc and stage IV) melanoma will be randomized to either treatment arm A (ipilimumab) or treatment arm B (TIL) after metastasectomy and feasibility ... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Ongoing) NL (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003497-48 | Sponsor Protocol Number: EMPATHY | Start Date*: 2021-11-29 | |||||||||||
Sponsor Name:Medical University of Warsaw | |||||||||||||
Full Title: Empagliflozin and dapagliflozin in patients hospitalized for acute decompensated heart failure (EMPATHY) – a phase III trial | |||||||||||||
Medical condition: acute decompensated heart failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-004252-37 | Sponsor Protocol Number: IPH1101-204 | Start Date*: 2007-10-11 | |||||||||||
Sponsor Name:Innate Pharma | |||||||||||||
Full Title: A Phase I/II open label study to assess efficacy and safety of IPH1101 associated with low dose of interleukin 2, as add-on therapy to imatinib in CML patients with residual molecular disease | |||||||||||||
Medical condition: Chronic Myeloid Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-018585-23 | Sponsor Protocol Number: A4061051 | Start Date*: 2010-12-21 | |||||||||||
Sponsor Name:Pfizer Inc 235 East 42nd Street, New York, NY10017 | |||||||||||||
Full Title: AG-013736 (axitinib) for the treatment of metastatic renal cell cancer (mRCC) | |||||||||||||
Medical condition: metastatic renal cell cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003614-13 | Sponsor Protocol Number: hzVSF_v13-0006 | Start Date*: 2020-12-18 | |||||||||||
Sponsor Name:ImmuneMed Inc. | |||||||||||||
Full Title: Efficacy and safety of intravenously administered hzVSF-v13 in patients with COVID-19 pneumonia: a phase II, proof of concept, multicentre, randomized, parallel-group, double-blind, placebo-control... | |||||||||||||
Medical condition: Moderate-to-severe COVID-19 pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001389-10 | Sponsor Protocol Number: IASO | Start Date*: 2017-09-28 | |||||||||||
Sponsor Name:Cambridge University Hospitals NHS Foundation Trust & University of Cambridge | |||||||||||||
Full Title: A phase II randomised placebo controlled double blinded trial of Interleukin 1 blockade in Acute Severe Colitis | |||||||||||||
Medical condition: Acute Severe Ulcerative Colitis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-003050-23 | Sponsor Protocol Number: VTX002-201 | Start Date*: 2021-10-25 | |||||||||||
Sponsor Name:Oppilan Pharma Ltd., wholy owned subsidiary of Ventyx Biosciences Inc. | |||||||||||||
Full Title: A Phase 2, Multicenter, Randomized, Double-Blind,Placebo-Controlled, Parallel-Group Study to Evaluate the Clinical Efficacy and Safety of VTX002 in Subjects with Moderately to Severely Active Ulcer... | |||||||||||||
Medical condition: Moderately to Severely Active Ulcerative Colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Ongoing) PL (Ongoing) HU (Ongoing) LT (Ongoing) IT (Ongoing) BG (Ongoing) SK (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001152-29 | Sponsor Protocol Number: 201956 | Start Date*: 2015-07-10 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
Full Title: A Long-term Access Programme for Subjects with Severe Asthma who Participated in a GSK-sponsored Mepolizumab Clinical Study | |||||||||||||
Medical condition: Subjects with severe asthma | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) GB (GB - no longer in EU/EEA) NL (Completed) FR (Completed) CZ (Completed) EE (Completed) SK (Completed) GR (Completed) BG (Completed) PL (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-005726-15 | Sponsor Protocol Number: 217102 | Start Date*: 2022-05-17 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||
Full Title: A 52-week, randomized, double-blind, double-dummy, parallel-group, multi-centre, non-inferiority study to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults with... | |||||||||||||
Medical condition: Relapsing or refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA) receiving standard of care (SoC) therapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) DE (Ongoing) IT (Ongoing) PL (Ongoing) HU (Ongoing) PT (Ongoing) NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.